Wilbur James
Known title: Chief Commercial OfficerCIK: 0001940931
Associated companies
Transaction History
| TXG | ▼ Sell | Open Market | 3,464 | $150K | 11/22/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 14,718 | $619K | 11/20/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 9,699 | $444K | 8/22/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 316 | $17K | 5/23/2023 | View on chart |
| TXG | ▲ Buy | Grant | 14,555 | $0 | 3/21/2023 | View on chart |
| TXG | ▲ Buy | Grant | 95,839 | $0 | 9/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.